Purpose:
BRCA1/2 counseling and mutation testing is recommended for high-risk women, but geographic barriers exist, and no data on the costs and yields of diverse delivery approaches are available.
Methods:
We performed an economic evaluation with a randomized clinical trial comparing telephone versus in-person counseling at 14 locations (nine geographically remote). Costs included fixed overhead, variable staff, and patient time costs; research costs were excluded. Outcomes included average per-person costs for pretest counseling; mutations detected; and overall counseling, testing, and disclosure. Sensitivity analyses were performed to assess the impact of uncertainty.
Results:
In-person counseling was more costly per person counseled than was telephone counseling ($270 [range, $180 to $400] v $120 [range, $80 to $200], respectively). Counselors averaged 285 miles round-trip to deliver in-person counseling to the participants (three participants per session). There were no differences by arm in mutation detection rates (approximately 10%); therefore, telephone counseling was less costly per positive mutation detected than was in-person counseling ($37,160 [range, $36,080 to$38,920] v $40,330 [range, $38,010 to $43,870]). In-person counseling would only be less costly than telephone counseling if the most favorable assumptions were applied to in personc ounseling and the least favorable assumptions were applied to telephone counseling.
Conclusion:
In geographically underserved areas, telephone counseling is less costly than in-person counseling.
Citing Articles
INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors.
Yi J, Ballard S, Walsh C, Friedman D, Ganz P, Jacobs L
Contemp Clin Trials. 2024; 148():107745.
PMID: 39561920
PMC: 11700757.
DOI: 10.1016/j.cct.2024.107745.
Randomized control trial comparing genetic counseling service delivery models in an underserved population.
Lahiri S, Mersch J, Zimmerman J, Mauer Hall C, Moriarty K, Gemmell A
J Genet Couns. 2024; 34(2):e1975.
PMID: 39370944
PMC: 11866741.
DOI: 10.1002/jgc4.1975.
The growing needs of genetic counselling-Feasibility in utilization of tele-genetic counselling in Asia and Hong Kong.
Chu A, Chung C, Hue S, Chung B
Front Genet. 2023; 14:1239817.
PMID: 37600657
PMC: 10435751.
DOI: 10.3389/fgene.2023.1239817.
Ethical, legal, and social implications (ELSI) and challenges in the design of a randomized controlled trial to test the online return of cancer genetic research results to U.S. Black women.
Wang C, Bertrand K, Trevino-Talbot M, Flynn M, Ruderman M, Cabral H
Contemp Clin Trials. 2023; 132:107309.
PMID: 37516165
PMC: 10544717.
DOI: 10.1016/j.cct.2023.107309.
Implementation of a Population-Based Cancer Family History Screening Program for Lynch Syndrome.
Lahiri S, Pirzadeh-Miller S, Moriarty K, Kubiliun N
Cancer Control. 2023; 30:10732748231175011.
PMID: 37161761
PMC: 10185972.
DOI: 10.1177/10732748231175011.
Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting.
Cao P, Smith L, Mandelblatt J, Jeon J, Taylor K, Zhao A
JNCI Cancer Spectr. 2022; 6(4).
PMID: 35818125
PMC: 9382714.
DOI: 10.1093/jncics/pkac048.
Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes.
Binion S, Sorgen L, Peshkin B, Valdimarsdottir H, Isaacs C, Nusbaum R
J Telemed Telecare. 2021; 30(2):334-343.
PMID: 34779303
PMC: 9902210.
DOI: 10.1177/1357633X211052220.
Virtual Care in Patients with Cancer: A Systematic Review.
Singh S, Fletcher G, Yao X, Sussman J
Curr Oncol. 2021; 28(5):3488-3506.
PMID: 34590602
PMC: 8482228.
DOI: 10.3390/curroncol28050301.
Telehealth Interventions Designed for Women: an Evidence Map.
Goldstein K, Zullig L, Dedert E, Tabriz A, Brearly T, Raitz G
J Gen Intern Med. 2018; 33(12):2191-2200.
PMID: 30284173
PMC: 6258612.
DOI: 10.1007/s11606-018-4655-8.
Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
Kinney A, Howell R, Ruckman R, McDougall J, Boyce T, Vicuna B
Contemp Clin Trials. 2018; 73:123-135.
PMID: 30236776
PMC: 6214814.
DOI: 10.1016/j.cct.2018.09.005.
Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
Steffen L, Du R, Gammon A, Mandelblatt J, Kohlmann W, Lee J
Cancer Epidemiol Biomarkers Prev. 2017; 26(12):1772-1780.
PMID: 28971986
PMC: 5712253.
DOI: 10.1158/1055-9965.EPI-17-0389.
Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing.
Cragun D, Kinney A, Pal T
Expert Rev Mol Diagn. 2016; 17(1):57-70.
PMID: 27910721
PMC: 5642111.
DOI: 10.1080/14737159.2017.1267567.
Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.
Kinney A, Steffen L, Brumbach B, Kohlmann W, Du R, Lee J
J Clin Oncol. 2016; 34(24):2914-24.
PMID: 27325848
PMC: 5012661.
DOI: 10.1200/JCO.2015.65.9557.